New method to monitor HPV16-related throat cancer recurrence

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial evaluates the use of HPV16 circulating DNA as a biomarker to improve post-therapeutic surveillance for patients with HPV-positive oropharyngeal squamous cell carcinoma. The study aims to determine if measuring HPV circulating DNA can help identify patients at risk for cancer recurrence, allowing for tailored follow-up strategies. Patients with undetectable HPV Ct-DNA may require fewer follow-up visits, while those with detectable levels may need closer monitoring. The goal is to enhance patient care and reduce healthcare costs associated with unnecessary surveillance.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Patient aged 18 years or over
2. Patient with p16 positive Oropharyngeal squamous cell carcinoma (OPSCC)
3. Clinical stage T1-4, N0-3, M0 (stages I-III)
4. Any tobacco status
5. Life expectancy greater than 36 months
6. Positive HPV16 Ct-DNA measured before curative anticancer treatment
7. Treated by any curative treatment
8. Complete response at 3 months after end of treatment, which means:

   * Undetectable HPV16 Ct-DNA and no residual disease on imaging (group A) or
   * Undetectable HPV16 Ct-DNA and suspicious imaging but persistent disease excluded by either biopsy or repeated imaging (group B1) or
   * Positive HPV16 Ct-DNA and no residual disease on imaging but negative HPV16 Ct-DNA on the subsequent assessment. This second test will be done 1-2 months after the first one (group C1).
9. Patient must be affiliated to a Social Security System (or equivalent)
10. Patients must have signed a written informed consent form prior to any trial specific procedures. If the patient is physically unable to give his/her written consent, a trusted person of his/her choice, note related to the investigator or the sponsor, can confirm in writing the patient's consent.

Exclusion Criteria:

1. Uncontrolled intercurrent illness that would limit compliance with study requirements.
2. Active invasive malignancy within 3 years of inclusion except for non-invasive malignancies such as non-melanomatous carcinoma of the skin or ductal carcinoma in situ of the breast that has/have been surgically cured.
3. Any other HPV induced cancer within 5 years
4. Any condition that may jeopardize the patient participation as well as non-contraception for male and female with child-bearing potential, pregnancy or breast-feeding
5. Patient unwilling or unable to comply with the study protocol and follow-up schedule.
6. Participation in another clinical trial with an investigational medical product during the last 30 days prior to the inclusion and during the present study (except if patient is included in the control arm, with placebo or with a product that have a marketed authorization, used as per the summary of product characteristics (SmPC) for the given indication).
7. Patient deprived of liberty or placed under protective custody or guardianship.

Where it's running

• ISC Avignon
  Avignon, France Recruiting
• Georges-François Leclerc
  Dijon, France Recruiting
• La Timone-AP-HM Marseille
  Marseille, France Recruiting
• Hôpital Européen Georges Pompidou
  Paris, France Recruiting
• TENON - APHP Paris
  Paris, France Recruiting
• Eugène Marquis-Rennes
  Rennes, France Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Sacituzumab govitecan plus cetuximab for recurrent or metastatic head and neck squamous cell cancer

  This trial will test whether combining sacituzumab govitecan with cetuximab works and is safe for people whose head and neck squamous cell cancer has returned or spread after prior immunotherapy.

  Recruiting at 7 sites Phase 2 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07063212

• New blood test to reduce radiation in HPV-related throat cancer treatment

  This study is testing a new blood test to see if it can help identify patients with HPV-related throat cancer who might not need radiation after surgery, aiming to reduce side effects while keeping survival rates high.

  Recruiting at 2 sites Phase 2 University of Maryland, Baltimore · Baltimore, Maryland and 4 other locations · NCT06088381

• Monitoring HPV DNA in patients with throat cancer

  This study is testing if checking for HPV DNA in the blood of throat cancer patients can help doctors spot any remaining cancer or recurrences after treatment.

  Recruiting Region Skane · Lund, Skåne County · NCT05649865

• Detecting oral and throat cancers using a saliva test

  This study is testing a saliva test to see if it can help detect oral and throat cancers early in people, including those who are healthy and those with existing conditions.

  Recruiting Viome · New York, New York · NCT05451303

• Observing HPV DNA and genetic markers in oropharyngeal cancer

  This study is testing if checking for certain gene changes and HPV DNA in the blood can help predict if oropharyngeal cancer will come back in newly diagnosed patients.

  Recruiting at 2 sites UNC Lineberger Comprehensive Cancer Center · Rochester, Minnesota and 2 other locations · NCT04564989

• Platform for studying biomarkers and treatments in head and neck cancer

  This study is trying to gather information on how well different treatments work for people with advanced head and neck cancer to help improve future care.

  Recruiting AIO-Studien-gGmbH · Essen and 1 other locations · NCT06380686

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.